Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-06

AUTHORS

Juan Martin-Liberal, Andrew JS Furness, Kroopa Joshi, Karl S. Peggs, Sergio A. Quezada, James Larkin

ABSTRACT

The anti programmed cell death-1 (PD-1) antibodies pembrolizumab and nivolumab have been recently licensed by the Food and Drug Administration for the treatment of advanced melanoma. Immune checkpoint inhibitors such as these can induce endocrine adverse events but autoimmune diabetes has not been described to date. However, there is a strong preclinical rationale that supports this autoimmune toxicity. We describe for the first time the case of an adult patient who developed autoimmune diabetes likely as a consequence of PD-1 inhibition with pembrolizumab. The presence of high serum titres of anti-glutamic acid decarboxylase antibodies together with a suggestive clinical presentation, age of the patient and preclinical data strongly support an autoimmune aetiology of the diabetes. Moreover, the patient was found to have a well-known high-risk human leucocyte antigen type for the development of type 1 diabetes in children, so the PD-1 inhibition is very likely to have triggered the autoimmune phenomenon. Our case suggests that insulin-dependent diabetes might be a rare but important anti-PD-1 immune-related adverse event. More... »

PAGES

765-767

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00262-015-1689-1

DOI

http://dx.doi.org/10.1007/s00262-015-1689-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016520120

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25828465


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Programmed Cell Death 1 Receptor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal Marsden Hospital", 
          "id": "https://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Renal and Melanoma Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martin-Liberal", 
        "givenName": "Juan", 
        "id": "sg:person.01165767756.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165767756.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University College London", 
          "id": "https://www.grid.ac/institutes/grid.83440.3b", 
          "name": [
            "Renal and Melanoma Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK", 
            "Cancer Immunology Unit, University College London Cancer Institute, 72 Huntley St, WC1E 6DD, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furness", 
        "givenName": "Andrew JS", 
        "id": "sg:person.01355106172.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355106172.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University College London", 
          "id": "https://www.grid.ac/institutes/grid.83440.3b", 
          "name": [
            "Renal and Melanoma Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK", 
            "Cancer Immunology Unit, University College London Cancer Institute, 72 Huntley St, WC1E 6DD, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Joshi", 
        "givenName": "Kroopa", 
        "id": "sg:person.01076201473.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076201473.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University College London", 
          "id": "https://www.grid.ac/institutes/grid.83440.3b", 
          "name": [
            "Cancer Immunology Unit, University College London Cancer Institute, 72 Huntley St, WC1E 6DD, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peggs", 
        "givenName": "Karl S.", 
        "id": "sg:person.0630024242.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630024242.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University College London", 
          "id": "https://www.grid.ac/institutes/grid.83440.3b", 
          "name": [
            "Cancer Immunology Unit, University College London Cancer Institute, 72 Huntley St, WC1E 6DD, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quezada", 
        "givenName": "Sergio A.", 
        "id": "sg:person.0636343635.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636343635.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden Hospital", 
          "id": "https://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Renal and Melanoma Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Larkin", 
        "givenName": "James", 
        "id": "sg:person.01255356274.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255356274.07"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1084/jem.20022125", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006579817"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clim.2007.05.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035686917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0089561", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038187260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1200694", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047413837"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.2003-031887", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064287452"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-06", 
    "datePublishedReg": "2015-06-01", 
    "description": "The anti programmed cell death-1 (PD-1) antibodies pembrolizumab and nivolumab have been recently licensed by the Food and Drug Administration for the treatment of advanced melanoma. Immune checkpoint inhibitors such as these can induce endocrine adverse events but autoimmune diabetes has not been described to date. However, there is a strong preclinical rationale that supports this autoimmune toxicity. We describe for the first time the case of an adult patient who developed autoimmune diabetes likely as a consequence of PD-1 inhibition with pembrolizumab. The presence of high serum titres of anti-glutamic acid decarboxylase antibodies together with a suggestive clinical presentation, age of the patient and preclinical data strongly support an autoimmune aetiology of the diabetes. Moreover, the patient was found to have a well-known high-risk human leucocyte antigen type for the development of type 1 diabetes in children, so the PD-1 inhibition is very likely to have triggered the autoimmune phenomenon. Our case suggests that insulin-dependent diabetes might be a rare but important anti-PD-1 immune-related adverse event. ", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00262-015-1689-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5141996", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1096240", 
        "issn": [
          "0340-7004", 
          "1432-0851"
        ], 
        "name": "Cancer Immunology, Immunotherapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "64"
      }
    ], 
    "name": "Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report", 
    "pagination": "765-767", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "4eb6b4037f2a3e04bacd5e6da5ac741ff76660779ab14aba357d3bf5b08c1006"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25828465"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8605732"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00262-015-1689-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016520120"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00262-015-1689-1", 
      "https://app.dimensions.ai/details/publication/pub.1016520120"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000531.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00262-015-1689-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00262-015-1689-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00262-015-1689-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00262-015-1689-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00262-015-1689-1'


 

This table displays all metadata directly associated to this object as RDF triples.

161 TRIPLES      21 PREDICATES      43 URIs      30 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00262-015-1689-1 schema:about N222df617361c4274a2247abda10853ca
2 N57ce3eff707142c59bc8d09605b69a98
3 N990cad2af8ed4f35879f978fa576ab8c
4 Na024e840207945b39c431c3c913c9b5f
5 Naa6a58ecdfbc4b38805a2fb838c5cd6b
6 Naaf5e27aa5154d9ea454fc8cbdb491df
7 Nb57e70b9533c45bda38f95af95456bd5
8 Nc3d268e13a8946ff897b2235ebb14d45
9 Ne1134cadea2e428098c23afdc9c619a1
10 anzsrc-for:11
11 anzsrc-for:1107
12 schema:author N4414364ee57f492d904c480a467f71d9
13 schema:citation https://doi.org/10.1016/j.clim.2007.05.013
14 https://doi.org/10.1056/nejmoa1200694
15 https://doi.org/10.1084/jem.20022125
16 https://doi.org/10.1210/jc.2003-031887
17 https://doi.org/10.1371/journal.pone.0089561
18 schema:datePublished 2015-06
19 schema:datePublishedReg 2015-06-01
20 schema:description The anti programmed cell death-1 (PD-1) antibodies pembrolizumab and nivolumab have been recently licensed by the Food and Drug Administration for the treatment of advanced melanoma. Immune checkpoint inhibitors such as these can induce endocrine adverse events but autoimmune diabetes has not been described to date. However, there is a strong preclinical rationale that supports this autoimmune toxicity. We describe for the first time the case of an adult patient who developed autoimmune diabetes likely as a consequence of PD-1 inhibition with pembrolizumab. The presence of high serum titres of anti-glutamic acid decarboxylase antibodies together with a suggestive clinical presentation, age of the patient and preclinical data strongly support an autoimmune aetiology of the diabetes. Moreover, the patient was found to have a well-known high-risk human leucocyte antigen type for the development of type 1 diabetes in children, so the PD-1 inhibition is very likely to have triggered the autoimmune phenomenon. Our case suggests that insulin-dependent diabetes might be a rare but important anti-PD-1 immune-related adverse event.
21 schema:genre research_article
22 schema:inLanguage en
23 schema:isAccessibleForFree false
24 schema:isPartOf Nb87b344a5a49475bb11da03adef4ee23
25 Ndc173147534b422686bc5d4037073b48
26 sg:journal.1096240
27 schema:name Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
28 schema:pagination 765-767
29 schema:productId N11f7fea36ec54745bb64e74e112d579b
30 N57369f3578e04287952c636eca1e5554
31 N65c24f96a11e4c7e8d83de174d116fae
32 Nb8a2abfa317a4af8abd569a6ac819baf
33 Nc0d09dabd6d44704a314185440e909e3
34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016520120
35 https://doi.org/10.1007/s00262-015-1689-1
36 schema:sdDatePublished 2019-04-10T16:46
37 schema:sdLicense https://scigraph.springernature.com/explorer/license/
38 schema:sdPublisher N10db2c1c113b4f808029f62a38b7b732
39 schema:url http://link.springer.com/10.1007%2Fs00262-015-1689-1
40 sgo:license sg:explorer/license/
41 sgo:sdDataset articles
42 rdf:type schema:ScholarlyArticle
43 N10db2c1c113b4f808029f62a38b7b732 schema:name Springer Nature - SN SciGraph project
44 rdf:type schema:Organization
45 N11f7fea36ec54745bb64e74e112d579b schema:name readcube_id
46 schema:value 4eb6b4037f2a3e04bacd5e6da5ac741ff76660779ab14aba357d3bf5b08c1006
47 rdf:type schema:PropertyValue
48 N1b52ca6ca4894f30a0a0cf1a0a24e0d2 rdf:first sg:person.0630024242.03
49 rdf:rest N6186ef3f6abd4992bcfc87a49c009c0e
50 N222df617361c4274a2247abda10853ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
51 schema:name Humans
52 rdf:type schema:DefinedTerm
53 N4414364ee57f492d904c480a467f71d9 rdf:first sg:person.01165767756.07
54 rdf:rest Nac66404473274ce5912cc1d65ab65826
55 N57369f3578e04287952c636eca1e5554 schema:name nlm_unique_id
56 schema:value 8605732
57 rdf:type schema:PropertyValue
58 N57ce3eff707142c59bc8d09605b69a98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Antibodies, Monoclonal, Humanized
60 rdf:type schema:DefinedTerm
61 N6186ef3f6abd4992bcfc87a49c009c0e rdf:first sg:person.0636343635.43
62 rdf:rest N9a5157a20dc346e8aeb40f35fb1592f2
63 N65c24f96a11e4c7e8d83de174d116fae schema:name dimensions_id
64 schema:value pub.1016520120
65 rdf:type schema:PropertyValue
66 N990cad2af8ed4f35879f978fa576ab8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Diabetes Mellitus, Type 1
68 rdf:type schema:DefinedTerm
69 N9a5157a20dc346e8aeb40f35fb1592f2 rdf:first sg:person.01255356274.07
70 rdf:rest rdf:nil
71 Na024e840207945b39c431c3c913c9b5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Melanoma
73 rdf:type schema:DefinedTerm
74 Naa6a58ecdfbc4b38805a2fb838c5cd6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Treatment Outcome
76 rdf:type schema:DefinedTerm
77 Naaf5e27aa5154d9ea454fc8cbdb491df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Programmed Cell Death 1 Receptor
79 rdf:type schema:DefinedTerm
80 Nac66404473274ce5912cc1d65ab65826 rdf:first sg:person.01355106172.98
81 rdf:rest Ncfacf51541c54861a9f04c2f905566ce
82 Nb57e70b9533c45bda38f95af95456bd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Female
84 rdf:type schema:DefinedTerm
85 Nb87b344a5a49475bb11da03adef4ee23 schema:volumeNumber 64
86 rdf:type schema:PublicationVolume
87 Nb8a2abfa317a4af8abd569a6ac819baf schema:name pubmed_id
88 schema:value 25828465
89 rdf:type schema:PropertyValue
90 Nc0d09dabd6d44704a314185440e909e3 schema:name doi
91 schema:value 10.1007/s00262-015-1689-1
92 rdf:type schema:PropertyValue
93 Nc3d268e13a8946ff897b2235ebb14d45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Antineoplastic Agents
95 rdf:type schema:DefinedTerm
96 Ncfacf51541c54861a9f04c2f905566ce rdf:first sg:person.01076201473.97
97 rdf:rest N1b52ca6ca4894f30a0a0cf1a0a24e0d2
98 Ndc173147534b422686bc5d4037073b48 schema:issueNumber 6
99 rdf:type schema:PublicationIssue
100 Ne1134cadea2e428098c23afdc9c619a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Middle Aged
102 rdf:type schema:DefinedTerm
103 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
104 schema:name Medical and Health Sciences
105 rdf:type schema:DefinedTerm
106 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
107 schema:name Immunology
108 rdf:type schema:DefinedTerm
109 sg:grant.5141996 http://pending.schema.org/fundedItem sg:pub.10.1007/s00262-015-1689-1
110 rdf:type schema:MonetaryGrant
111 sg:journal.1096240 schema:issn 0340-7004
112 1432-0851
113 schema:name Cancer Immunology, Immunotherapy
114 rdf:type schema:Periodical
115 sg:person.01076201473.97 schema:affiliation https://www.grid.ac/institutes/grid.83440.3b
116 schema:familyName Joshi
117 schema:givenName Kroopa
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076201473.97
119 rdf:type schema:Person
120 sg:person.01165767756.07 schema:affiliation https://www.grid.ac/institutes/grid.424926.f
121 schema:familyName Martin-Liberal
122 schema:givenName Juan
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165767756.07
124 rdf:type schema:Person
125 sg:person.01255356274.07 schema:affiliation https://www.grid.ac/institutes/grid.424926.f
126 schema:familyName Larkin
127 schema:givenName James
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255356274.07
129 rdf:type schema:Person
130 sg:person.01355106172.98 schema:affiliation https://www.grid.ac/institutes/grid.83440.3b
131 schema:familyName Furness
132 schema:givenName Andrew JS
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355106172.98
134 rdf:type schema:Person
135 sg:person.0630024242.03 schema:affiliation https://www.grid.ac/institutes/grid.83440.3b
136 schema:familyName Peggs
137 schema:givenName Karl S.
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630024242.03
139 rdf:type schema:Person
140 sg:person.0636343635.43 schema:affiliation https://www.grid.ac/institutes/grid.83440.3b
141 schema:familyName Quezada
142 schema:givenName Sergio A.
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636343635.43
144 rdf:type schema:Person
145 https://doi.org/10.1016/j.clim.2007.05.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035686917
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1056/nejmoa1200694 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047413837
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1084/jem.20022125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006579817
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1210/jc.2003-031887 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064287452
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1371/journal.pone.0089561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038187260
154 rdf:type schema:CreativeWork
155 https://www.grid.ac/institutes/grid.424926.f schema:alternateName Royal Marsden Hospital
156 schema:name Renal and Melanoma Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK
157 rdf:type schema:Organization
158 https://www.grid.ac/institutes/grid.83440.3b schema:alternateName University College London
159 schema:name Cancer Immunology Unit, University College London Cancer Institute, 72 Huntley St, WC1E 6DD, London, UK
160 Renal and Melanoma Unit, The Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK
161 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...